INVA - Innoviva Inc logo

INVA

Innoviva Inc

Innoviva Inc develops and markets biopharmaceuticals, including respiratory treatments like RELVAR/BREO ELLIPTA and ANORO ELLIPTA, along with antibiotics such as XERAVA and ZEVTERA. The company focuses on managing royalties and developing new therapies.

βš•οΈ Healthcare NASDAQ Listed 2004 $ USD
$1,000 invested 20 years ago β†’$1,061today

Score Overview

1 Year
Score
Net Growth31.74%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth4.31%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score4.9
Net Growth34.37%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth13.16%
Rev Trend60%
Revenue Consistencyβ€”
10 Years
Score
Net Growth6x
Net Trend60%
Net Income Consistency
Rev Growth231.99%
Rev Trend80%
Revenue Consistency
20 Years
Score5.5
Net Growth315.15%
Net Trend70%
Net Income Consistency
Rev Growth22x
Rev Trend75%
Revenue Consistency
All Time
Score
Net Growth448.00%
Net Trend64%
Net Income Consistency
Rev Growth49x
Rev Trend77%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Innoviva Inc has ranked, year by year

Measure
Fundamentals Window

Showing 1 year ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • INVA

2010: 24.9% Β· 2021: 10.9% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 21.23β€”
1 Year2025-09-26
$ 18.8612.57%
5 Years2021-09-28
$ 17.2023.43%
10 Years2016-09-28
$ 11.2189.38%
20 Years2006-09-28
$ 20.006.13%
All Time2004-10-05
$ 13.5556.71%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 443M$ 357M$ 570M
2025$ 425M$ 271M$ 550M
2024$ 358M$ 23M$ 412M
2023$ 310M$ 179M$ 193M
2022$ 331M$ 213M$ 291M
2021$ 391M$ 265M$ 201M
2020$ 336M$ 224M$ 246M
2019$ 261M$ 157M$ 350M
2018$ 261M$ 395M$ 114M
2017$ 217M$ 134M$ 129M
2016$ 133M$ 59M$ 150M
2015$ 53M-$ 18M$ 187M
2014$ 8M-$ 168M$ 240M
2013$ 4M-$ 170M$ 465M
2012$ 5M-$ 18M$ 248M
2011$ 24M-$ 115M$ 240M
2010$ 24M-$ 83M$ 309M
2009$ 24M-$ 85M$ 155M
2008$ 23M-$ 93M$ 200M
2007$ 22M-$ 159M$ 126M
2006$ 19M-$ 166M$ 201M
2005$ 12M-$ 143M$ 161M
IPO2004$ 8M-$ 102M$ 257M
INVA - Innoviva Inc logo

Innoviva Inc fundamental performance

Between 2015 and 2025, revenue grew from $ 53M to $ 425M and net income went from -$ 18M to $ 271M. Revenue increased in 8 of those 10 years; net income in 6.

Between 2005 and 2025, revenue grew from $ 12M to $ 425M and net income went from -$ 143M to $ 271M. Revenue increased in 15 of those 20 years; net income in 14.

Innoviva Inc currently holds a 20-year HDB Score of 5.5 out of 10. How the HDB Score is calculated.

Membership

Continue INVA’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies